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ABSTRACT 22 
Since the 1950’s, medical communities have been facing with Emerging and Re-emerging 23 
infectious diseases (EIDs) and they are now considered as the main microbiological public health 24 
threat. In this review, we focus on bacterial emerging diseases and explore factors involved in 25 
their emergence as well as future challenges. We identified 26 major EIDs of bacterial origin; 26 
most of them originated either from an animal and are considered as zoonoses or from water 27 
sources. Major contributing factors in the emergence of these bacterial infections are 1) 28 
Development of new diagnostic tools, such as improvements in culture methods, development of 29 
molecular techniques and implementation of mass-spectrometry in microbiology, 2) Increase in 30 
human exposure to bacterial pathogens due to sociodemographic and environmental changes and 31 
3) Emergence of more virulent bacterial strains and opportunistic infections, especially affecting 32 
immunocompromised populations. Precise definition of their implication in human diseases is 33 
challenging and requires the comprehensive integration of microbiological, clinical and 34 
epidemiological aspects, as well as the use of experimental model. It is now urgent to allocate 35 
financial resources to gather international data to provide a better understanding of the clinical 36 
relevance of these waterborne and zoonotic emerging diseases.  37 
38 
39 
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INTRODUCTION  40 
With the discovery of Penicillin by Henri Pasteur in 1928 and the many scientific progress that 41 
followed during the 20th century, it was thought that bacterial diseases would be easily controlled 42 
[1]. However, since the 1950’s, physicians have been facing with Emerging Infectious Diseases 43 
(EID) and Re-Emerging Infectious Diseases, which have brought significant public health and 44 
financial challenges. As an example, in 2010, specialists struggled with a mysterious clinical 45 
picture that associated a severe inflammatory syndrome with vascular events such as venous 46 
thromboembolisms or transient ischemic attacks. At least ten cases were described, especially in 47 
patients suffering from either autoimmune diseases or hematologic malignancies [2]. Despite 48 
multiple investigations, no microbiological agent was identified and no clinical improvement 49 
was observed on various antibiotics regimen, until an eubacterial 16sRNA PCR, followed by 50 
genome sequencing revealed the presence of Neoehrlichia mikurensis. This strict intracellular 51 
bacterium is related to Ehrlichia spp., the agent of human ehrlichiosis, and is emerging as a tick-52 
borne zoonotic pathogen. Patients were subsequently switch to doxycycline and rapidly showed 53 
significant improvements.  54 
EIDs represent infections that have recently appeared among humans or that are rapidly 55 
spreading among humans in term of incidence or geographical distribution [3]. Though known to 56 
be an issue from millennia, there has been an increased interest from the scientific community 57 
and EIDs are now considered as one of the main microbiological public health threat [4].  58 
In this review, after an historical back-sight, we will first explore the factors associated with 59 
emergence of bacterial pathogens, secondly, the approaches that may be used to confirm their 60 
pathogenic role in humans and, finally, future challenges.  61 
62 
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HISTORY 63 
During the last 40 years, at least 50 emerging infectious agents have been identified [5], among 64 
them approximately 10% are bacterial agents [6]. Similarly to N. mikurensis, some of these show 65 
distinct clinical pictures and require specific diagnostic tools and peculiar antibiotic treatments.  66 
In table 1, we present 26 major emerging bacterial pathogens identified during the last 50 years. 67 
We decided to include in this table only new genera and species belonging to a previously 68 
characterized genus only when the later caused a clearly distinct clinical entity than the other 69 
species in the genus (i.e Chlamydia pneumoniae). Thus, the list is far from being complete and 70 
does not include all newly discovered pathogenic species. For example, before 1984, only 8 71 
species of the genus Rickettsia were known to be pathogenic in human, two of the typhus group 72 
and 6 of the spotted fever group (SFG). Currently, at least 25 species of the SFG are recognized, 73 
most of which are pathogenic to humans or strongly suspected to be [7–10]. In addition, new 74 
virulent strains of known species have been discovered such as the enterohemorragic Escherichia 75 
coli (O104:H4) who caused a large outbreak of Hemolytic Uremic Syndrome, in 2011, in 76 
Germany, and was associated with sprout consumption [11,12].  77 
78 
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WHY DO PATHOGENS EMERGE? 79 
Why do bacterial pathogens keep emerging? Antigenic drift due to random mutations is a 80 
common mechanism in the emergence of viral diseases such as SARS and HIV. Opposite to 81 
viruses, bacteria possess a more stable genome and, thus, bacterial divergence following random 82 
mutations is less common. Therefore, are we truly confronted to new pathogenic species/strains 83 
or are we simply confronted to the indefinite biodiversity of the prokaryote world? 84 
Retrospectively, it seems that most EIDs are due to bacteria that have long been present in our 85 
environment [3], but that humans have only been recently exposed to or that we were unable to 86 
detect so far. With that in mind, three main aspects need to be discussed to understand the 87 
dynamics of bacterial diseases emergence: 1) Development of new diagnostic tools, 2) Increase 88 
in human exposure to bacterial pathogens, 3) Emergence of more virulent bacterial strains and 89 
opportunistic infections.  90 
 91 
1. Development of new diagnostic tools 92 
Identification of a bacterium traditionally depends on culture. However, traditional culture 93 
media, as invented by Pasteur, are quite limited and do not allow culture of all bacteria. In 94 
addition, differentiation between species might not be possible based only on culture properties. 95 
Isolation of recent emerging bacteria was achieved through a) Improvement of traditional culture 96 
techniques and development of cell culture b) Molecular techniques and c) Implantation of mass 97 
spectrometry in microbiology.  98 
99 
 Culture. Adjunction of specific antibiotics or selective substrates to broad-spectrum 100 
media, as well as optimization of culture duration and temperature, or pre-inoculation filtration 101 
ACCEPTED MANUSCRIPT
 6
and plate centrifugation have significantly improved the efficiency of traditional culture [13]. 102 
Thus, prolongation of the incubation up to 12 weeks (instead of 6 weeks) allowed the recovery 103 
from patients’ blood of various Mycobacterium, especially M. genaveniae, that would otherwise 104 
remain undetected [14]. Additional examples of such improvements are the isolation of the 105 
enterohemorrhagic Escherichia coli using a sorbitol-MacConkey media [15] and the culture of 106 
Campylobacter spp. or Helicobacter spp. using a selective antibiotic-containing media [16,17]. 107 
Similarly, specific media have also been developed such as the Kelly media allowing the culture 108 
of Borrelia spp. [18]. Finally, cell culture played a significant role in the identification of 109 
emerging bacteria, as many of recently discovered species are strict intracellular bacteria. 110 
Historically, these bacteria were recovered using animal models or embryonated eggs. Various 111 
cell culture models can be used: mammalian cells, such as HEL cell lines, which enabled the 112 
recovery of Tropheryma whipplei from a cardiac valve biopsy [19] and monocytes cell lines, 113 
which were used to isolate Ehrlichia spp. [20]. Nevertheless, since bacteria often present host 114 
restriction, non-mammalian cell models such as amoebae have been used. Amoebae are 115 
extremely useful to discover new microorganisms, either through amoebae co-culture or amoebal 116 
enrichment, especially in highly contaminated samples such as water or sputum [21]. Indeed, 117 
most amoebae feed on other bacteria and they are, therefore, less subject to contamination. This 118 
technique has enabled to isolate various Chlamydia-related bacteria, such as Parachlamydia 119 
acanthamoebae [22], Estrella lausannensis [23,24] or Criblamydia sequanensis [25]. Culture 120 
with arthropods cell lines is a promising model to help identify arthropods-transmitted zoonotic 121 
agents. In addition to allow recovery and identification of otherwise uncultivable bacteria, cell 122 
culture provides a higher sensitivity than traditional culture. For example, the isolation of 123 
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Bartonella quintana from a skin biopsy was only possible using culture with endothelial cell 124 
lines [26]. 125 
 126 
 Molecular techniques and metagenomics. PCR has long been used to detect bacteria in 127 
various specimens. However, in the 1980s, universal primers targeting the 16S rRNA gene have 128 
been developed [27–29] and have enabled the identification of various emerging bacteria such as 129 
T. whipplei [30,31], E. chaffeensis [32] and, as mentioned, N. mikurensis [2]. Such primers 130 
amplify most bacteria present in a clinical or environmental sample and the subsequent 131 
sequencing of the amplicons allows species determination. In addition, development of Next-132 
Generation Sequencing (NGS), based on pyrosequencing (Illumina, 454) or proton-sequencing 133 
(Ion Torrent) [33] has largely facilitated broad sequencing of PCR products offering a complete 134 
view of the microbiome present. PCR-based and direct metagenomics studies are now widely 135 
used to study flora modifications associated with diseases such as inflammatory bowel disease 136 
and ecosystems modifications. As an example, a recent study analyzed the gut flora of preterm 137 
babies with Necrotizing Enterocolitis (NEC) and revealed a strong association with the presence 138 
of Clostridium butyricum [34]. 139 
Broad-range PCR are especially useful to diagnose bacterial infections in otherwise sterile body 140 
sites, such as blood, heart valves, joints, central nervous system and pleura, but cannot be used 141 
for non-sterile samples such as sputum, feces or vaginal specimens. Order or family-restricted 142 
PCRs such as the recently developed Pan-Chlamydiales PCR are an alternative to overcome this 143 
limitation. This PCR has been used to detect emerging pneumonia-associated pathogens [35], as 144 
well as to demonstrate the common presence of Chlamydiales in ticks [36].  145 
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To summarize, molecular techniques are extremely powerful to identify unknown bacteria. First, 146 
they overcome the culture limitations of fastidious organisms. Second, they are highly sensitive 147 
with a detection limit as low as 5 copies and are, therefore, extremely useful to detect bacteria 148 
after empirical antibiotic treatments or in cases of latent infections, such as Q fever in cattle, for 149 
which PCR has been shown to be extremely useful to identify animals with active shedding [37]. 150 
Finally, they enable a better taxonomic affiliation and many emerging bacteria were classified or 151 
reclassified after analysis of their 16s RNA gene.  152 
153 
Mass spectrometry. MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionisation 154 
Time of Flight Mass Spectrometry) was initially used in clinical chemistry and was then adapted 155 
to identify bacteria by using acidic matrix specifically extracting small basic proteins such as 156 
ribosomal proteins. Since 2010, this technique has been used in microbiology laboratories to 157 
detect bacteria from clinical samples, with excellent results in term of specificity and time gain 158 
compared to culture [38]. This technique allowed the easier identification of emerging urinary 159 
pathogens such as Aerococcus spp. or Actinobaculum spp.[39,40]. MALDI-TOF MS may also be 160 
applied to strict intracellular bacteria and provides some phenotypic information essential for 161 
thorough polyphasic taxonomic affiliation [24].  162 
 163 
2. Increase in human exposure to bacterial pathogens  164 
Our environment represents an indefinite reservoir of prokaryote species among which some 165 
carry a potential pathogenic role towards humans. First, as shown in table 1, most recent 166 
emerging bacterial diseases derive from animals and are therefore considered as zoonoses.  167 
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Zoonotic agents can be transmitted to humans either through i) direct contacts ii) bites or 168 
scratches iii) arthropods vectors iv) consumption of contaminated food and v) contact with 169 
carcasses or feces-contaminated environmental sources such as water or soil [41]. An alternate 170 
important reservoir for prokaryotes is water sources, notably through amoebae-contaminated 171 
water. Finally, many bacteria with a potential pathogenic role are part of the normal flora in 172 
humans. During the last century, major sociodemographic and environmental changes have 173 
disrupted the dynamic equilibrium that exists between humans, prokaryotes and their 174 
environment and led to an increase in human exposure to some environmental pathogenic 175 
species, as well as person-to-person transmission of commensal bacteria. 176 
 177 
 a. Sociodemographic changes. Successful emergence of novel infectious agent  178 
generally requires their rapid dissemination among human populations. Therefore, the increase in 179 
population density has been a significant factor in diseases emergence as illustrated by the 180 
epidemic of plague in the 14th century or by the dissemination of scrub typhus, caused by 181 
Orentia tsutsugamushi, among allied troop during World War II. Currently, the densification of 182 
the population, especially in hospital settings, and the increasing use of invasive procedures have 183 
increased health care-associated infections, such as Clostridium difficile infections, which now 184 
represent a significant public health challenge [42].  185 
In addition, nowadays, populations have not only increased in number, but have also increased 186 
the speed and rate by which they move across the earth, enabling rapid spatial dissemination of 187 
pathogens. This is explained by globalization, which has led to a dramatic increase in 188 
international trade and commercial transportations, population migrations and the reduction in 189 
the traveling expenses, which has increased the number of leisure travels to exotic destinations. 190 
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This is further accompanied by an increase in merchandise and alimentary products’ movements, 191 
potentially bringing with them tropical diseases. An excellent example is provided by the re-192 
emergence of cholera (Vibrio cholerae O1) in South America, in 1991, which is thought to be 193 
linked to the bilge water dumping of an Asian merchant ship off the Peruvian coast with 194 
subsequent infection of over 1.4 million people over 6 years [43]. Owing to international travels, 195 
cases were then reported in the United States and, in 1992, 75 out of 336 passengers of a plane 196 
returning to Los Angeles from Argentina were infected due to the presence of V. cholerae in the 197 
seafood salad served onboard, prepared by a Peruvian caterer [44,45]. 198 
Additionally, since 1950’s leisure activities have increased due to an increased interest in self-199 
development enabled by more flexible working hours and higher wages. Outdoors activities such 200 
as hiking are now common and put population at risk of arthropods-transmitted diseases, such as 201 
Lyme disease [46], Spotted Fever [47] or Chlamydia-related bacteria infections, as shown by two 202 
recent Swiss studies [36,48]. Similarly, people possess more pets, not only cats and dogs, but 203 
also reptiles, exotic fishes and guinea pigs, which are reservoir of a further variety of bacterial 204 
pathogens [49]. 205 
Modern convenience has led to the dissemination of air-conditioning systems and humidifiers, 206 
which both contain stagnant water and produce aerosols. As shown by the Legionella outbreak in 207 
1976, these increase the risk of infection by amoebal-resistant micro-organisms (legionella, 208 
mycobacteria) and such systems might be the reservoir of emerging respiratory pathogens, such 209 
as Parachlamydia acanthamoebae or Simkania negevensis [50,51]. 210 
 211 
 b. Environmental changes. Over the last 50 years, we have been facing with some 212 
climatic changes, which have significantly modified our ecology. For example, warmer winters, 213 
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experienced nowadays, tend to increase rodent populations in the summer, increasing their 214 
contacts with humans [3]. Climatic changes have probably played a significant role in the 215 
emergence of V. cholerae O139, in Bangladesh, in 1992. Marine life, such as algae or copepods, 216 
acts as a reservoir for V. cholerae spp., in which they can subsist in a dormant form; under 217 
favorable conditions such as warming, they can reactivate and propagate among marine spp. 218 
[52]. In addition, warming also increases algal blooms, with which epidemics of cholera seem 219 
associated [53]. Congruently, V. cholerae O139 first appeared in coastal zones and the heavy 220 
monsoon that occurred in 1993 might have increased its dissemination [52].  221 
Similarly, modifications of our environment brought by industrialization,, such as deforestations 222 
and reforestations or development of damsand agriculture, change ecosystems and their relations 223 
with humans. Dams will increase arthropods populations, cultivated lands attract animals and it 224 
is well known that the emergence of Lyme disease was associated with the reforestation of some 225 
peri-urban regions [54].  226 
  227 
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3. Emergence of more virulent bacterial strains and opportunistic infections 228 
In the last 20 years, medical communities have been facing with the apparition of multidrug 229 
resistant species such as Methicillin-Resistant S. aureus (MRSA/MSSA), Multidrug or 230 
Extensively Resistant Tuberculosis (MDR-TB/XDR-TB), Vancomycin Resistant Enterococcus 231 
(VRE) and Extended Beta-lactamase E.coli (ESBL). Due to their rapid dissemination among 232 
hospitalized patients and the general population, these may be considered as emerging pathogens 233 
and require significant attention. Nevertheless, this major public health issue is outside the scope 234 
of the present review and due to the complexity of the phenomenon, it will not be discussed here. 235 
In addition, there have been significant concerns about the development of virulent laboratory 236 
bacterial strains and bioterrorism, especially after the 2001 Anthrax attack. Though, these aspects 237 
need to be taken into account when discussing emerging bacterial diseases, they remain 238 
extremely rare and were recently reviewed [55].  239 
More importantly, atypical syndromes due to commonly inoffensive bacteria have appeared 240 
among vulnerable populations, such as the potential lethal bacillary angiomatosis caused by B. 241 
henselae or B. quintana in HIV patients, which are often asymptomatic in the general population. 242 
Over the last 30 years, there has been an increase in the number of patients with impaired 243 
immune systems. The recent advances in medicine partly contribute to this phenomenon 244 
enabling higher survival rates of patients with cancer, chronic diseases, such as renal 245 
insufficiency and diabetes, or transplant therapies. Additional contributing factors comprise 246 
population ageing and, on the opposite, a higher rate of preterm babies, the epidemic of HIV, and 247 
common usage of immunosuppressive therapy in the management of autoimmune diseases. 248 
Cases of invasive infections, such as sepsis or endocarditis, caused by non-diphteria 249 
Corynebacterium spp. are additional illustrations [56,57] These bacteria are normal resident of 250 
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the skin and mucosa and are, therefore, often thought as being a contaminant when found in 251 
cultures delaying the diagnosis. This can further have a significant impact on medical 252 
management as many of them, such as C. amycolatum, are multidrug resistant [57,58]. 253 
Additionally, such patients may be at risk of severe infections due to environmental bacteria, 254 
such as Capnocytophaga canimorsus that has now emerged as a cause of septicemia in 255 
splenectomized or cirrhotic patients bitten by dogs [59]. 256 
 257 
  258 
 259 
  260 
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NEW DOES NOT MEAN PATHOGENIC 261 
The recent advances in microbiological diagnosis have enlarged the number of identifiable 262 
prokaryotes enhancing the difficulty to determine the one that are pathogenic from all beneficial 263 
or harmless microbes. Congruently, the DATABASE GenBank reports an increase in bacterial 264 
nucleotides sequences submitted per year of 21% [60] and one can understand why some authors 265 
fear an “epidemic of emerging infectious diseases” [61]. Historically, the confirmation of the 266 
pathogenic role of a microorganism required the fulfillment of 4 criteria, established by Koch in 267 
1890 [62] (exposed in table 2). However, these postulates are limited when considering 268 
opportunistic infections, uncultured organisms, toxin-related pathologies and more recently 269 
microbial-associated neoplasia (HPV, EBV, H. pylori) or auto-immune diseases (Reiter’s 270 
syndrome). Some authors suggest that they have became obsolete and have proposed additional 271 
criteria (see table 2) [63–65]. As mentioned, molecular studies have helped identifying causative 272 
agents of emerging diseases, especially for organisms with fastidious growth requirements and 273 
one can ask whether culture is still required. However, PCR identify both living and dead 274 
bacteria, as well as bacterial fragments. Moreover, due to its high sensitivity, it is subject to 275 
samples’ contaminations during the process of samplings, extraction or amplification. This 276 
aspect has already been questioned in studies evaluating the association between Chlamydia 277 
pneumoniae and atherosclerosis [66]. To overcome these limitations, Fredricks and Relman have 278 
established some principles to guide the use of molecular studies (Table 2) [63]. However, the 279 
sole isolation of bacterial nucleic acids from a patient does not prove causation of the disease and 280 
additional criteria are required. Indeed, though identification of E. chaffeensis was done by PCR, 281 
evidence of its pathogenic role were brought by the visualization of typical morulae within 282 
leucocytes and serological evidence [67]. Similarly, the excellent antibiotic response strongly 283 
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supports the role of N. mikurensis in cases described earlier. With that in mind and the already 284 
proposed criteria (table 2), we recommend the following elements, exposed in table 3, to be 285 
taken into account to determine the pathogenic role of a recently isolated bacterium. However, 286 
with the more complex nature of recent infectious diseases, it is hopeless to think that every 287 
criterion can be strictly met and we should not expect absolute comparisons such as absent or 288 
present, but refer to relative differences that make an epidemiological sense. For example, the 289 
correlation between serology and direct identification of C. pneumoniae through PCR is not good 290 
[68] and might be explained by a delay (2-3 weeks) in the apparition of IgM [69]; the association 291 
between pneumonia and C. pneumoniae is, nevertheless, commonly accepted. Similarly, the very 292 
high proportion of the population exhibiting a positive serology to C. pneumoniae makes it 293 
impossible to use IgG for epidemiological studies investigating possible long term complications 294 
that may be associated with this new pathogen, such as asthma exacerbation or bronchial 295 
hyperactivity, as suspected by recent studies [70–72]. Finally, certain bacteria present some host 296 
restriction and the development of experimental animal is not possible. 297 
 298 
  299 
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FUTURE CHALLENGES 300 
It will be difficult and even hopeless to control the emergence of new bacterial diseases. 301 
However, efforts can be made to rapidly identify epicenter of potential epidemics using notably 302 
new technologies such as social networks and media in order to prevent the uncontrolled spread 303 
of emerging diseases. The example provided by the Haitian cholera outbreak mapping, in 2010, 304 
based on social and media reports is promising [73]. In addition, resources should be allocated (i) 305 
to perform clinical studies of quality to precisely define the clinical relevance of recently 306 
discovered bacteria, (ii) to develop accurate diagnostic tools and (iii) to assess the benefits of 307 
antibiotic treatments to prevent inadequate antibiotic usage. International collaborations are of 308 
utmost importance since globalization has increased infectious diseases dissemination and to 309 
avoid low-powered studies leading to inconclusive results. It should be emphasized that 310 
microbes are not only associated with infectious diseases, but, as outlined above, also with non-311 
infectious diseases such as asthma or cancers; therefore research on emerging pathogens should 312 
not only focus on emerging infections, but more broadly on new pathologies that may be 313 
associated with these newly discovered bacterial agents. Finally, efforts should be made to 314 
increase general population knowledge on emerging diseases and to provide a scientific-315 
validated message of the actual risks to ensure adequate medical seeking following exposure and 316 
compliance to general preventive measures.  317 
318 
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TABLES 595 
Table 1: Major emerging bacterial pathogens of the last 50 years 596 
Abbreviations: PPI, proton pump inhibitor; UTI, urinary tract infection 597 
 598 
1Suggested as examples of commonly used antimicrobial therapy. It should be adapted to local 599 
recommendations 600 
  601 
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Table 1 : Major emerging bacterial pathogens of the last 50 years 
Year Bacterial species Diseases Comments Transmission Antibiotic treatment1 References
1973 Campylobacter spp. Diarrhea 
Zoonosis (Poultry, cattle, 
uncooked meat, 
unpasteurized milk)
Unnecessary in most cases 
(Macrolides; quinolones) [17,74]
1974 Clostridium difficile Pseudo membrane colitis; toxic 
megacolon  
Commonly associated with 
antibiotic use Part of the normal flora Vancomycin [75,76]
1974 Streptococcus bovis group Endocarditis  
Commonly associated with 
adenocarcinoma of the colon and 
chronic liver diseases
Part of the normal flora 
and/or Zoonosis 
(Contaminated food)
Betalactam [77,78,79]
1976 Legionella pneumophila Lung infection Amoebae in water Azithromycin; respiratory quinolones [80,81]
1976 Capnocytophaga 
canimorsus Sepsis
In asplenic patients, hepatic 
diseases, alcohol abuse Zoonosis (Dogs)
Betalactam-Betalactamase 
combinations; cephalosporin; 
carbapenem
[82]
1981 Staphylococcus aureus Toxin Toxic shock syndrome Associated with tampon use
Skin and mucous membrane 
colonization Vancomycin + clindamycin [83]
1982 Escherichia coli O157:H7 Hemorrhagic colitis, Hemolytic 
uremic syndrome Known as "Hamburger disease"
Zoonosis (Contaminated 
food) not required [84]
1982 Borrelia burgdoferi Lyme disease Zoonosis (Ticks) Doxycycline; amoxicillin [85]
1983 Chlamydia pneumoniae Lung infection 
First isolated in 1965 in the 
context of trachoma vaccine trial 
in the eye
Person to person  Macrolides, doxycycline [86]
1983 Helicobacter pylori Gastric ulcers
Associated with a higher risk of 
gastric adenocarcinoma and 
lymphoma
Person to person PPI + Clarithromycin + Amoxicillin/Metronidazole [16]
1986 Rhodococcus equi Pneumonia in immunosuppressed Zoonosis (Herbivores 
especially horses)
Multidrug therapy due to 
resistance [87]
1987 Ehrlichia chaffeensis Human ehrlichiosis Zoonosis (Ticks) Doxycycline [32, 67]
1990's non-diphtheria Corynebacterium spp.
Endocarditis in immunosuppressed, 
patients with underlying valve 
disease or prosthetic valve; other 
invasive infections
Most important: C. amycolatum 
initially confounded as C. xerosis, 
C. striatum
Part of the normal flora Betalactam + glycopeptides; if resistant vancomycin
[57, 58, 
87-90]
1990's Spotted fever group Rickettsia spp. Spotted fever rickettsiosis
Notably R. africae, R. helveticae, 
R. slovaca, R. mongolotimonae Zoonosis (Ticks) Doxycycline [8, 9, 91-93]
1990 Anaplasma phagocytophilum Human granulocytic anaplasmosis Previously thought to be an Ehrilichia  spp. Zoonosis (Ticks) Doxycycline [94, 95]
1991 Tropheryma whipplei Whipple's disease ?
Ceftriaxone followed by 
trimethoprim-
sulfamethoxazole 
[30, 31]
1992 Vibrio cholerae O139 Diarrhea Contaminated water Not required [96]
1992 Bartonella henselae Cat-scratch disease, bacillary 
angiomatosis Initially named Rochalimaea Zoonosis (Cats)
Generally not required in 
immunocompetant [97, 98]
1992 Aerococcus spp. UTI, endocarditis 
Mainly A. urinae  and A. 
sanguinicola ; especially in elderly 
or patients predisposing factors 
such as diabetes, urinary 
catheters
Part of the normal flora (?), 
person to person 
transmission
Betalactam, glycopeptides, [99, 100]
1995 Wolbachia spp. Associated with onchocerciasis and lymphatic filariasis
Indirectly acts as an 
endosymbionts of filarial 
nematodes increasing their 
pathogenicity 
Filarial nematodes Doxycycline +/- antifilarial 
treatment
[101-103]
1997 Simkania negevensis Lung infection ? Macrolides, doxycycline [104]
1997 Actinobaculum schaalii UTI 
First considered as a contaminant 
; especially in elderly or patients 
predisposing factors such as 
diabetes, urinary catheters
? Betalactam, glycopeptides, [105]
1997 Parachlamydia acanthamoebae Lung infection
Isolated from the water of an 
humidifier involved in an epidemic 
of fever in Vermont 
Amoebae in water (?) Macrolides; doxycycline [106]
2007 Waddlia chondrophila Miscarriages ? Macrolides; doxycycline [107]
2007 Alloscardovia omnicolens UTI
Especially in elderly or patients 
predisposing factors such as 
diabetes, urinary catheters
?
Betalactam, cotrimoxazole, 
glycopeptides, 
fluroquinolones
[108]
2010 Neoehrlichia mikurensis 
Neoehrlichiosis : Systemic 
inflammatory response; Vascular 
and thromboembolic events 
More frequent among 
immunocompromised patients Zoonosis (Ticks) Doxycycline [109-111]
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Table 2: Historical principles established to determine microbial disease causation 603 
This table is adapted from the following historical references [62–65,112] 604 
 605 
1This principle was not part of the initial Koch’s postulates, but was added later on by reviewers. 606 
607 
608 
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Table 3: Recommended considerations to determine the causative nature of a given new 610 
bacterial disease 611 
612 
613 
614 
615 
616 
617 
618 
619 
620 
621 
622 
 623 
1Low bacterial load are commonly observed with Mycobacterium tuberculosis and Chlamydia 624 
trachomatis despite their obvious pathogenic role 625 
626 
627 
